{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T13:15:59Z","timestamp":1788095759078,"version":"build-2803163510"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jns.2020.116706","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T11:16:34Z","timestamp":1579778194000},"page":"116706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Leptomeningeal metastasis from solid tumors"],"prefix":"10.1016","volume":"411","author":[{"given":"Jigisha P.","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan S.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4115-6370","authenticated-orcid":false,"given":"Rimas V.","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2020.116706_bb0005","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","article-title":"Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology","volume":"29","author":"Glass","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.116706_bb0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-811161-1.00013-X","article-title":"Leptomeningeal metastasis","volume":"149","author":"Taillibert","year":"2018","journal-title":"Handb. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00005792-198201000-00005","article-title":"Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience","volume":"61","author":"Rosen","year":"1982","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0002-9343(81)90254-0","article-title":"Meningeal carcinomatosis in small cell carcinoma of the lung","volume":"71","author":"Aroney","year":"1981","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","article-title":"Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients","volume":"49","author":"Wasserstrom","year":"1982","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-008-9758-3","article-title":"Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors","volume":"93","author":"Waki","year":"2009","journal-title":"J. Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","article-title":"Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis","volume":"114","author":"Yust-Katz","year":"2013","journal-title":"J. Neuro-Oncol."},{"issue":"18","key":"10.1016\/j.jns.2020.116706_bb0040","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","article-title":"Leptomeningeal metastases in the MRI era","volume":"74","author":"Clarke","year":"2010","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1634\/theoncologist.8-5-398","article-title":"Diagnosis and management of central nervous system metastases from breast cancer","volume":"8","author":"Chang","year":"2003","journal-title":"Oncologist."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/JNS\/2008\/108\/2\/0248","article-title":"Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa","volume":"108","author":"Suki","year":"2008","journal-title":"J. Neurosurg."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0055","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3171\/2012.1.JNS111560","article-title":"Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection","volume":"116","author":"Ahn","year":"2012","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","article-title":"The seed and soil hypothesis: vascularisation and brain metastases","volume":"3","author":"Fidler","year":"2002","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/157339411797642597","article-title":"Leptomeningeal metastasis: challenges in diagnosis and treatment","volume":"7","author":"Leal","year":"2011","journal-title":"Curr. Cancer Ther. Rev."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ana.410170121","article-title":"Leptomeningeal metastases: reduction in regional cerebral blood flow and cognitive impairment","volume":"17","author":"Siegal","year":"1985","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.74.1.13","article-title":"Constipation in neurological diseases","volume":"74","author":"Winge","year":"2003","journal-title":"J. Neurol. Neurosurg.Amp. Psychiatry"},{"key":"10.1016\/j.jns.2020.116706_bb0080","series-title":"National Comprehensive Cancer Network","first-page":"2019","author":"Guidelines N","year":"2019"},{"issue":"suppl_4","key":"10.1016\/j.jns.2020.116706_bb0085","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0090","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","article-title":"Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results","volume":"82","author":"Glantz","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0022-510X(94)90159-7","article-title":"A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid","volume":"121","author":"Dux","year":"1994","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1097-0339(200012)23:6<369::AID-DC1>3.0.CO;2-3","article-title":"Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis","volume":"23","author":"French","year":"2000","journal-title":"Diagn. Cytopathol."},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0115","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/nov273","article-title":"EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors","volume":"18","author":"Milojkovic Kerklaan","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00172659","article-title":"Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors","volume":"12","author":"Nakagawa","year":"1992","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-014-1361-1","article-title":"CSF CA 15-3 in breast cancer-related leptomeningeal metastases","volume":"117","author":"Le Rhun","year":"2014","journal-title":"J. Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdy544","article-title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","volume":"30","author":"Seoane","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jns.2020.116706_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-018-0706-x","article-title":"The utility of liquid biopsy in central nervous system malignancies","volume":"20","author":"Nevel","year":"2018","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11523-019-00645-5","article-title":"Digital PCR-based detection of EGFR mutations in paired plasma and CSF samples of lung adenocarcinoma patients with central nervous system metastases","volume":"14","author":"Huang","year":"2019","journal-title":"Target. Oncol."},{"issue":"9","key":"10.1016\/j.jns.2020.116706_bb0145","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s004150050459","article-title":"The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis","volume":"246","author":"Straathof","year":"1999","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-003-0085-8","article-title":"Toxicity of treatment for neoplastic meningitis","volume":"5","author":"Siegal","year":"2003","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-009-9940-2","article-title":"Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy","volume":"95","author":"Clatot","year":"2009","journal-title":"J. Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J. Neuro-Oncol."},{"issue":"11","key":"10.1016\/j.jns.2020.116706_bb0165","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0170","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1215\/15228517-2008-062","article-title":"Prognostic factors and outcomes in patients with leptomeningeal melanomatosis","volume":"10","author":"Harstad","year":"2008","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis--the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jns.2020.116706_bb0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","article-title":"Leptomeningeal metastasis: clinical experience of 519 cases","volume":"56","author":"Hyun","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jns.2020.116706_bb0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2017.07.015","article-title":"Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: a single-Centre experience","volume":"36","author":"Kingston","year":"2017","journal-title":"Breast."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"Suppl. 4","key":"10.1016\/j.jns.2020.116706_bb0205","first-page":"S265","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.jns.2020.116706_bb0210","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fonc.2018.00641","article-title":"Palliative radiotherapy for Leptomeningeal Carcinomatosis-analysis of outcome, prognostic factors, and symptom response","volume":"8","author":"El Shafie","year":"2018","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0360-3016(94)00413-F","article-title":"Quantitative magnetic resonance and isotopic imaging: early evaluation of radiation injury to the brain","volume":"32","author":"Miot","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jns.2020.116706_bb0220","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fimmu.2017.00517","article-title":"Ionizing radiation-induced immune and inflammatory reactions in the brain","volume":"8","author":"Lumniczky","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2020.116706_bb0225","series-title":"Neurologic Complications Of Cancer","author":"JB. P","year":"1995"},{"key":"10.1016\/j.jns.2020.116706_bb0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/0-387-24199-X_9","article-title":"Radiation therapy for leptomeningeal cancer","volume":"125","author":"Mehta","year":"2005","journal-title":"Cancer Treat. Res."},{"issue":"24","key":"10.1016\/j.jns.2020.116706_bb0235","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jns.2020.116706_bb0240","article-title":"NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain mevtastases (BM)","volume":"37","author":"Vinai Gondi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jns.2020.116706_bb0245","series-title":"Nervous System Drug Delivery. Central Nervous System Drug Delivery After Ischemic or Hemorrhagic Stroke","author":"Nguyen Hoang","year":"2019"},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0250","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for Leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.jns.2020.116706_bb0255","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/80.15.1211","article-title":"Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study","volume":"80","author":"Burch","year":"1988","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0260","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1227\/00006123-198908000-00015","article-title":"Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody","volume":"25","author":"Benjamin","year":"1989","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0265","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(25)30311-3","article-title":"Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion","volume":"195","author":"Blasberg","year":"1975","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2020.116706_bb0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fonc.2018.00509","article-title":"The comparative treatment of Intraventricular chemotherapy by Ommaya reservoir vs. lumbar puncture in patients with Leptomeningeal Carcinomatosis","volume":"8","author":"Montes de Oca Delgado","year":"2018","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.jns.2020.116706_bb0280","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jns.2020.116706_bb0285","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4047617","article-title":"Complications of Intrathecal chemotherapy in adults: single-institution experience in 109 consecutive patients","volume":"2019","author":"Byrnes","year":"2019","journal-title":"J Oncol."},{"issue":"5\u20136","key":"10.1016\/j.jns.2020.116706_bb0290","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/08880018.2018.1524536","article-title":"Treatment of two cases on the same day of intrathecal methotrexate overdose using cerebrospinal fluid exchange and intrathecal instillation of carboxypeptidase-G2","volume":"35","author":"Wormdal","year":"2018","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/NCC.0000000000000108","article-title":"Intrathecal chemotherapy: potential for medication error","volume":"37","author":"Gilbar","year":"2014","journal-title":"Cancer Nurs."},{"issue":"35","key":"10.1016\/j.jns.2020.116706_bb0300","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.2174\/1381612822666160726112115","article-title":"Potential pathways for CNS drug delivery across the blood-cerebrospinal fluid barrier","volume":"22","author":"Strazielle","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2020.116706_bb0305","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2377-9-S1-S3","article-title":"Characteristics of compounds that cross the blood-brain barrier","volume":"9","author":"Banks","year":"2009","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-3565(25)12972-8","article-title":"Distribution of drugs between blood and cerebrospinal fluid: general methodology and effect of ph gradients","volume":"125","author":"Rall","year":"1959","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0315","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0320","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jfma.2015.03.005","article-title":"Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis","volume":"115","author":"Chen","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"issue":"12","key":"10.1016\/j.jns.2020.116706_bb0325","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/15384047.2018.1491504","article-title":"Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report","volume":"19","author":"Jing","year":"2018","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.jns.2020.116706_bb0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2016.07.008","article-title":"Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer","volume":"99","author":"Sakata","year":"2016","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.jns.2020.116706_bb0335","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0340","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0345","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bjc.6605586","article-title":"Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience","volume":"102","author":"Sutherland","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0350","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0355","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-013-2754-0","article-title":"A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases","volume":"142","author":"Lin","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"13","key":"10.1016\/j.jns.2020.116706_bb0360","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: a phase II trial of Neratinib and Capecitabine for patients with human epidermal growth factor receptor 2-positive breast Cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jns.2020.116706_bb0365","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib combined with ado-Trastuzumab Emtansine in advanced ERBB2\/HER2-positive metastatic breast Cancer: a phase 1b clinical trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.jns.2020.116706_bb0370","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","article-title":"Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study","volume":"19","author":"Murthy","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0375","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"13","key":"10.1016\/j.jns.2020.116706_bb0380","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0385","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cncr.22088","article-title":"A phase I\/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer","volume":"107","author":"Milton","year":"2006","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0390","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","article-title":"High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer","volume":"99","author":"Clarke","year":"2010","journal-title":"J. Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0395","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-018-0566-1","article-title":"Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung Cancer suffering from brain metastases and\/or Leptomeningeal disease","volume":"13","author":"Hochmair","year":"2018","journal-title":"Target. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0405","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.jns.2020.116706_bb0410","first-page":"4177","article-title":"Cerebrospinal fluid penetration rate and efficacy of Afatinib in patients with EGFR mutation-positive non-small cell lung cancer with Leptomeningeal Carcinomatosis: a Multicenter prospective study","volume":"37","author":"Tamiya","year":"2017","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0415","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"25","key":"10.1016\/j.jns.2020.116706_bb0420","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","article-title":"Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors","volume":"28","author":"Yap","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0425","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.lungcan.2014.06.002","article-title":"Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis","volume":"85","author":"Lin","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jns.2020.116706_bb0430","series-title":"Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study. Paper Presented at: ASCO2017","author":"Yang","year":"2017"},{"issue":"15_suppl","key":"10.1016\/j.jns.2020.116706_bb0435","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2017.35.15_suppl.2020","article-title":"Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study","volume":"35","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.jns.2020.116706_bb0440","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","article-title":"Multicenter phase II study of whole-body and intracranial activity with Ceritinib in patients with ALK-rearranged non-small-cell lung Cancer previously treated with chemotherapy and Crizotinib: results from ASCEND-2","volume":"34","author":"Crino","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jns.2020.116706_bb0445","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0450","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-016-0400-x","article-title":"Novel treatment strategies for brain metastases in non-small-cell lung cancer","volume":"17","author":"Bui","year":"2016","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"8","key":"10.1016\/j.jns.2020.116706_bb0455","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1097\/JTO.0000000000000174","article-title":"LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer","volume":"9","author":"Arrondeau","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0460","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/JTO.0000000000000455","article-title":"Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib","volume":"10","author":"Gainor","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"26","key":"10.1016\/j.jns.2020.116706_bb0465","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of Brigatinib activity in patients with anaplastic lymphoma kinase-positive non\u2013small-cell lung cancer and brain metastases in two clinical trials","volume":"36","author":"Camidge","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0470","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0475","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CMR.0000000000000162","article-title":"Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma","volume":"25","author":"Sakji-Dupre","year":"2015","journal-title":"Melanoma Res."},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0480","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2020.116706_bb0485","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1391-x","article-title":"Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jns.2020.116706_bb0490","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/CMR.0000000000000257","article-title":"Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival","volume":"26","author":"Floudas","year":"2016","journal-title":"Melanoma Res."},{"issue":"11","key":"10.1016\/j.jns.2020.116706_bb0495","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1200\/JCO.2012.46.5773","article-title":"Vemurafenib for leptomeningeal melanomatosis","volume":"31","author":"Schafer","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0500","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CMR.0b013e32835e589c","article-title":"Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report","volume":"23","author":"Lee","year":"2013","journal-title":"Melanoma Res."},{"issue":"28","key":"10.1016\/j.jns.2020.116706_bb0505","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1200\/JCO.2013.48.7298","article-title":"Complete cytologic remission of V600E BRAF-mutant melanoma-associated Leptomeningeal Carcinomatosis upon treatment with Dabrafenib","volume":"33","author":"Wilgenhof","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jns.2020.116706_bb0510","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jns.2020.116706_bb0515","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.2018.36.15_suppl.2007","article-title":"Phase II study of pembrolizumab in leptomeningeal carcinomatosis","volume":"36","author":"Brastianos","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jns.2020.116706_bb0520","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0525","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0530","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma","volume":"27","author":"Geukes Foppen","year":"2016","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jns.2020.116706_bb0535","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2020.116706_bb0540","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"issue":"suppl_2","key":"10.1016\/j.jns.2020.116706_bb0545","article-title":"81OSafety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases","volume":"28","author":"Lukas","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2020.116706_bb0550","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0555","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/pcmr.12652","article-title":"Leptomeningeal melanoma-a case series in the era of modern systemic therapy","volume":"31","author":"Arasaratnam","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.jns.2020.116706_bb0560","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.jns.2020.116706_bb0565","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","article-title":"Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid","volume":"34","author":"Pentsova","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jns.2020.116706_bb0570","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2016.34.15_suppl.2004","article-title":"ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer","volume":"34","author":"Kumthekar","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jns.2020.116706_bb0575","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"19","key":"10.1016\/j.jns.2020.116706_bb0580","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0585","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0590","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002371-200201000-00009","article-title":"Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases","volume":"25","author":"Guirguis","year":"2002","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0595","first-page":"703","article-title":"Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection","volume":"61","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rep."},{"issue":"6","key":"10.1016\/j.jns.2020.116706_bb0600","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/clpt.1984.120","article-title":"Cytosine arabinoside cerebrospinal fluid kinetics","volume":"35","author":"Zimm","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0605","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/107327481702400104","article-title":"Neoplastic meningitis due to lung, breast, and melanoma metastases","volume":"24","author":"Le Rhun","year":"2017","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.jns.2020.116706_bb0610","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/15228517-2007-059","article-title":"A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies","volume":"10","author":"Groves","year":"2008","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0615","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.2003.04.053","article-title":"Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis","volume":"21","author":"Blaney","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jns.2020.116706_bb0620","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00685957","article-title":"Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data","volume":"29","author":"van der Gaast","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.jns.2020.116706_bb0625","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/cncr.21828","article-title":"Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis","volume":"106","author":"Chamberlain","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jns.2020.116706_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-012-1893-z","article-title":"Intra-CSF administration of chemotherapy medications","volume":"70","author":"Gabay","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.jns.2020.116706_bb0635","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jns.2020.116706_bb0640","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/cncr.23859","article-title":"Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases","volume":"113","author":"Addeo","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jns.2020.116706_bb0645","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:49:19Z","timestamp":1758383359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20300423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":129,"alternative-id":["S0022510X20300423"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116706","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptomeningeal metastasis from solid tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116706"}}